Journal of Pharmacogenomics & Pharmacoproteomics

Clinical Proteomics: Protein-Based Insights for Diagnosis, Treatment Assessment, and Patient Care

Isabella Romano ^* Department of Clinical Biochemistry, University of Milan, Milan, Italy
^*Correspondence: Isabella Romano, Department of Clinical Biochemistry, University of Milan, Milan, Italy, Email:

Received: 29-Aug-2025 , Manuscript No. JPP-25-32623; Editor assigned: 01-Sep-2025 , Pre QC No. JPP-25-32623; Reviewed: 15-Sep-2025 , QC No. JPP-25-32623; Revised: 22-Sep-2025 , Manuscript No. JPP-25-32623; Published: 29-Sep-2025 , DOI: 10.35248/2153-0645.25.16.147

Description

Clinical proteomics is the analysis of proteins and their molecular characteristics in biological samples to obtain information relevant to human health and disease. Proteins perform essential functions in cells, including signaling, transport, metabolism, immune defense, structural support and communication between tissues. Changes in protein abundance, structure, location, or chemical modification can accompany disease processes. Measuring these changes can provide useful information for diagnosis, disease classification, treatment selection, safety assessment and monitoring of therapeutic responses.

Proteins are dynamic molecules whose levels can change according to age, nutrition, infection, medication exposure, tissue damage and disease activity. Unlike Deoxyribonucleic Acid (DNA), which remains relatively stable in most cells, protein profiles can change rapidly in response to physiological and pathological conditions. This makes protein measurements useful for examining current biological activity. Clinical proteomics can therefore complement genomic and transcriptomic information by providing a view of molecular activity at the protein level. Blood is one of the most commonly examined biological materials in clinical proteomics because it can contain proteins released from many tissues. Plasma and serum contain thousands of proteins with concentrations ranging from very abundant molecules to proteins present at extremely low levels. Albumin and immunoglobulins are among the most abundant proteins, while signaling molecules and disease-associated proteins may occur at much lower concentrations. Analytical methods must therefore distinguish relevant signals within a highly complex mixture.

Mass spectrometry is an important technology used in clinical proteomics. Proteins are commonly digested into smaller peptides, which are separated and analyzed according to their physical and chemical properties. The resulting signals can be matched with protein databases to identify the proteins present in a sample. Quantitative approaches can also compare protein abundance between different patient groups or clinical conditions. Immunoassays provide another important method for clinical protein measurement. These techniques use antibodies that recognize specific proteins or molecular targets. Enzyme-linked immunosorbent assays and related platforms can measure selected biomarkers in blood and other biological samples. Such methods are widely used when a particular protein has established clinical relevance and requires routine measurement.

Cancer is a major area of clinical proteomics. Tumor cells can produce proteins at levels that differ from normal tissues and some proteins may undergo changes in phosphorylation, glycosylation, or other modifications. Protein profiling can help characterize tumor biology and identify molecular features associated with disease progression or treatment response. Tissue-based proteomic information can also complement genomic findings by showing which molecular pathways are active within a tumor. Clinical proteomics is also relevant to cardiovascular medicine. Heart injury, vascular inflammation, thrombosis and changes in cardiac function can influence circulating protein concentrations. Cardiac troponins are established protein biomarkers used in the assessment of myocardial injury. Additional protein markers are being evaluated for their ability to provide information about inflammation, vascular activity, heart failure and other cardiovascular conditions.

Neurological disorders present another area where protein analysis can provide useful information. Proteins in cerebrospinal fluid, blood and other biological materials may reflect changes associated with neuronal injury, inflammation, or abnormal protein processing. Protein measurements can contribute to the characterization of neurological conditions and may assist in monitoring disease-associated molecular changes. Inflammation and immune activity can also be assessed through protein measurements. Cytokines, chemokines, complement proteins, acute-phase proteins and immunoglobulins can change during infection or immune activation. Measuring these proteins can provide information about inflammatory activity and may help distinguish different clinical conditions when combined with symptoms and other laboratory findings.

Post-translational modifications add another layer of information to clinical proteomics. Phosphorylation can alter protein activity and cellular signaling, while glycosylation can influence protein stability, recognition and interactions. Ubiquitination can affect protein degradation and cellular regulation. Measuring these modifications can provide information that may not be visible when only total protein abundance is examined. Clinical proteomics can also support medication response assessment. A medicine may alter the abundance or modification of specific proteins within a pathway. Tracking these changes can provide information about whether the intended biological process is being affected. Protein measurements may also identify molecular patterns associated with treatment resistance or unwanted effects.

Biomarker development is an important application of clinical proteomics. A biomarker is a measurable biological characteristic associated with a physiological or pathological process. Protein biomarkers can be used for diagnosis, prognosis, treatment monitoring and safety assessment. A useful biomarker should demonstrate reliable measurement, appropriate specificity, sensitivity and a meaningful association with the clinical condition being evaluated. Bioinformatics is essential for handling proteomic datasets. Modern instruments can generate large numbers of peptide and protein measurements from a single sample. Computational platforms can organize these data, compare molecular profiles, identify altered proteins and connect protein changes with biological pathways. Statistical analysis helps distinguish meaningful patterns from technical variation.